Sale

Iron Deficiency Anaemia Treatment Market

Global Iron Deficiency Anaemia Treatment Market Size, Share, Demand, Research: By Drug Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumarate, Ferric Hydroxide, Sodium Ferric Gluconate, Iron Carbohydrates, Others; By Therapy: Oral Iron Therapy, Others; By Treatment Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Iron Deficiency Anaemia Treatment Market Outlook

The iron deficiency anaemia treatment market size was valued at USD 4.5 billion in 2023. The market is likely to grow at a CAGR of 15.31% during the forecast period of 2024-2032 to attain a value of about USD 16.20 billion by 2032.

 

iron deficiency anaemia treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Company News

In June 2021, a generic version of Feraheme was launched by Sandoz to treat patients with iron deficiency anaemia with Ferumoxytol, a high-dose intravenous iron supplement. The generic version of ferrahem (ferumoxytol injection), produced by AMAG Pharmaceuticals was approved to treat IDA in adults suffering from oral iron intolerance or chronic kidney disease, who do not respond well to oral iron.

 

In January 2020, the U.S. Food and Drug Administration (FDA) approved ferric derisomaltose injection, manufactured by PHARMACOSMOS A/S, for treating chronic kidney disease patients who cannot tolerate or are irresponsive to oral iron, or who are not dependent on haemodialysis for treating iron deficiency anaemia.

 

Introduction

A condition called anaemia occurs when the red blood cells (RBCs) or the haemoglobin concentration is insufficient. The body's tissues need haemoglobin to carry oxygen, and when a person has too few red blood cells, is malformed, or has no haemoglobin, then blood is unable to carry oxygen.

 

The main symptom of anaemia is a low number of red blood cells, which can cause paleness, fatigue, and weakness. The subtypes are classified according to the chronicity, size, and aetiology of the RBCs.

 

The loss of blood and decrease in red blood cell production can lead to anaemia due to an iron deficiency or an increase in red blood cell destruction by haemolysis. The main cause of anaemia is iron deficiency.

 

Iron levels can be used to categorize IDAs into mild, moderate, and severe categories. Symptoms and signs of mild to moderate disease are usually absent. Symptoms related to the severe form include fatigue, shortness of breath, or chest pain.

 

IDA (iron deficiency anaemia) is characterized by iron deficiency. This may be mainly due to low iron intake. IDA can also be caused by blood loss, an inability to absorb iron, and other health issues.

 

IDA is usually diagnosed by a physical exam and blood tests. In order to determine if the body has enough normal blood cells, iron and ferritin, a complete blood count is appropriate.

 

Treatment begins once IDA is diagnosed. Patients' characteristics and disease severity determine the treatment procedure. Increased consumption of iron supplements is the most common and the first prescribed treatment by doctors.

 

The supplements can be taken orally (Auryxia, Accrufer, and OTC) or intravenously (Venofer, Feraheme, and Monofer, among others). A blood transfusion or surgery may be needed in extreme/serious cases.

 

According to the global iron deficiency anaemia treatment market research report, the market can be categorised into the following segments:

 

iron deficiency anaemia treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Drug Type

  • Ferrous Sulphate
  • Ferrous Gluconate
  • Ferrous Fumarate
  • Ferric Hydroxide
  • Sodium Ferric Gluconate
  • Iron Carbohydrates
  • Others

 

Market Breakup by Route of Administration

  • Tablets
  • Capsules
  • Liquids

 

Market Breakup by Treatment Channel

  • Public
  • Private

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

iron deficiency anaemia treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Prevalence, Rising Investment for Healthcare Infrastructure, Increasing Research and Development Activities to be the Key Market Trends

The growth of the iron deficiency anaemia treatment market is primarily driven by the rising prevalence of the disease as well as chronic kidney diseases. The market is also propelled by other factors such as the rapidly developing healthcare infrastructure.

 

The growth of the market can also be attributed to the rising awareness about the disease as well as its treatment by the public and private organisations.


Rising disposable incomes of the populations and the increased risk of blood dilution will also increase the demand for iron deficiency anaemia treatments. As the population ages and people lead sedentary lifestyles, the market is expected to grow further in the coming years.

 

The market is also witnessing rapid growth due to the increasing research and development activities. As a result, the market is expected to grow significantly over the next few years.

 

In addition, the approval and launch of more drugs is expected to accelerate the market growth. Rising investment in advanced technology and growth in emerging markets will act as lucrative opportunities for the growth of the iron deficiency anaemia treatment market in the coming years.

 

Factors like High Costs of the Treatment and Lack of Professionals are Restricting the Growth of the Market

The high cost of the treatment will hamper the growth of the market as most of the patients are unable to afford it. In the developing countries, iron deficiency anaemia treatment market will be challenged by a lack of skilled professionals and medical infrastructure.

 

North America Dominates the Global Iron Deficiency Anaemia Treatment Market

North America dominates the iron deficiency anaemia treatment market due to the region's well-established healthcare infrastructure. The key players will be increasingly interested in new technologies, which will add further growth to the market.

 

It is expected that the Asia Pacific region will also witness significant growth over the forecast period due to population growth and rise in healthcare spending.

 

Therapeutic Landscape

It is common for IDA patients to be prescribed oral iron supplements in pill, tablet, or syrup form in the early stages. There are several over the counter (OTC) iron remedies available in the market. The gastrointestinal side effects of oral iron reduce patient compliance. It is recommended to use intravenous iron if the patient no longer responds to these drugs or if the drugs are not working as effectively as before.

 

IDA Approved Drugs

Auryxia (Riona/ KRX-0502/Ferric Citrate): Akebia Therapeutics

Due to its unique chemical properties and mechanism of action, Auryxia is a calcium-free iron-based compound that doubles as a treatment for CKD patients. This drug contains a small molecule called ferric citrate as its active ingredient.

 

Immediately following its approval by the US Food and Drug Administration (FDA) in September 2014, the drug was marketed in the United States as a phosphate binder for hyperphosphatemia. It was approved by the FDA in 2017 for IDA, a second indication for treatment of adult patients.

 

Feraccru/Accrufer (Ferric Maltol/ ST10): Shield Therapeutics

Feraccru/Accrufer provides an alternative to intravenous iron therapy for patients who are intolerant to oral iron supplements.

 

Feraheme/Rienso (Ferumoxytol): AMAG Pharmaceuticals

For intravenous use, Feraheme contains ferumoxytol as a replacement for iron. It is an inorganic magnetite (superparamagnetic iron oxide) coated with polyglucose sorbitol carboxymethyl ether.

 

Clinical Trials

 

IDA Emerging Drugs

MPB-1514 (IOP Injection): MegaPro Biomedical

MegaPro Biomedical is developing MPB-1514/IOP injection for the treatment of IDA that is sugar-free. It is extremely safe as it follows doctor's prescription. The PEG coating would allow high-dose administration and lead to an increase in red blood cells without frequent injections. Currently, the drug is the only sugar-free injection in development.

 

IDAX (IHAT-02): Nemysis

Nemysis (IHAT-02/IDAX) is the first ferritin-mimic product that uses a tartrate salt to insulate the ferrihydrite nanocore of adipate-buffered ferritin. IHAT is well absorbed and maintains healthy gut bacteria. IHAT has been shown to be efficiently absorbed by humans and correct markers of iron deficiency without causing gastrointestinal side effects. As a result of this product, iron can be absorbed in the intestine in a manner similar to what happens naturally.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global iron deficiency anaemia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • Amgen Inc.
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc
  • Janssen Pharmaceuticals, Inc.
  • AMAG Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Type
  • Therapy
  • Treatment Channel
  • Region
Breakup by Drug Type
  • Ferrous Sulphate
  • Ferrous Gluconate
  • Ferrous Fumarate
  • Ferric Hydroxide
  • Sodium Ferric Gluconate
  • Iron Carbohydrates
  • Others
Breakup by Therapy
  • Oral Iron Therapy
  • Parenteral Iron Therapy
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc
  • Janssen Pharmaceuticals, Inc.
  • AMAG Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Covis Group S.
  • Apotex
  • Akebia Therapeutics, Inc.
  • American Regent, Inc.
  • Bayer Ag
  • Merck & Co.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Iron Deficiency Anaemia Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Current Scenario Evaluation and Regulatory Framework
    6.1    Emerging Therapies and Clinical Trials Synopsis
    6.2    Patent Landscape
        6.2.1    Patent Overview
            6.2.1.1    Patent Status and Expiry
            6.2.1.2    Timelines from Drug Development to Commercial Launch
            6.2.1.3    New Drug Application
                6.2.1.3.1    Documentation and Approval Process
    6.3    Cost of Treatment
    6.4    Regulatory Framework
        6.4.1    Regulatory Overview
            6.4.1.1    US FDA
            6.4.1.2    EU EMA
            6.4.1.3    INDIA CDSCO
            6.4.1.4    JAPAN PMDA
            6.4.1.5    Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop-Out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Iron Deficiency Anaemia Treatment Market
    8.1    Global Iron Deficiency Anaemia Treatment Market Overview
    8.2    Global Iron Deficiency Anaemia Treatment Market Analysis 
        8.2.1     Market Overview
            8.2.1.1    Global Iron Deficiency Anaemia Treatment Market Historical Value (2017-2023) 
            8.2.1.2    Global Iron Deficiency Anaemia Treatment Market Forecast Value (2024-2032)
    8.3    Global Iron Deficiency Anaemia Treatment Market by Drug Type
        8.3.1     Market Overview
            8.3.1.1    Ferrous Sulphate
            8.3.1.2    Ferrous Gluconate
            8.3.1.3    Ferrous Fumarate 
            8.3.1.4    Ferric Hydroxide
            8.3.1.5    Sodium Ferric Gluconate
            8.3.1.6    Iron Carbohydrates
            8.3.1.7    Others
    8.4    Global Iron Deficiency Anaemia Treatment Market by Therapy
        8.4.1     Market Overview
            8.4.1.1    Oral Iron Therapy
                8.4.1.1.1    Capsules
                8.4.1.1.2    Liquids
            8.4.1.2    Parenteral Iron Therapy
                8.4.1.2.1    Red Blood Cell Transfusion 
            8.4.1.3    Others
    8.5    Global Iron Deficiency Anaemia Treatment Market by Treatment Channel
        8.5.1    Market Overview
            8.5.1.1     Public
            8.5.1.2     Private
    8.6    Global Iron Deficiency Anaemia Treatment Market by Region
        8.6.1     Market Overview
            8.6.1.1    North America
            8.6.1.2    Europe 
            8.6.1.3    Asia Pacific
            8.6.1.4    Latin America 
            8.6.1.5    Middle East and Africa
9    North America  Iron Deficiency Anaemia Treatment Market
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Iron Deficiency Anaemia Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Iron Deficiency Anaemia Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Iron Deficiency Anaemia Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Iron Deficiency Anaemia Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Global Iron Deficiency Anaemia Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model
    14.4    Key Demand Indicators
    14.5    Key Price Indicators
    14.6    Industry Events, Initiatives, and Trends 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Amgen Inc.
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    F. Hoffmann-La Roche Ltd
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Novartis A.G.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Pfizer Inc.
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Janssen Pharmaceuticals, Inc.
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    AMAG Pharmaceuticals
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Teva Pharmaceutical Industries Ltd.
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    Zydus Lifesciences Ltd.
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Covis Group S.
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Apotex
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
    15.11    Akebia Therapeutics, Inc.
        15.11.1    Company Overview
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications
    15.12    American Regent, Inc.
        15.12.1    Company Overview
        15.12.2    Product Portfolio
        15.12.3    Demographic Reach and Achievements
        15.12.4    Mergers and Acquisitions
        15.12.5    Certifications
    15.13    Bayer Ag
        15.13.1    Company Overview
        15.13.2    Product Portfolio
        15.13.3    Demographic Reach and Achievements
        15.13.4    Mergers and Acquisitions
        15.13.5    Certifications
    15.14    Merck & Co.
        15.14.1    Company Overview
        15.14.2    Product Portfolio
        15.14.3    Demographic Reach and Achievements
        15.14.4    Mergers and Acquisitions
        15.14.5    Certifications
16    Global Iron Deficiency Anaemia Treatment Market- Drug Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment 
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of around USD 4.5 billion in 2023, driven by the rising prevalence of anaemia, especially amongst women.

The market is likely to grow at a CAGR of 15.31% during the forecast period of 2024-2032 to reach a value of USD 16.20 billion by 2032.

The high prevalence of chronic kidney disease, increasing number of patients and presence of major players focused on development, and marketing of technologically advanced products will drive the growth during the forecast period.

North America is the dominating region in the global market owing to the rising demand for the treatment in the region.

Amgen Inc., Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Janssen Pharmaceuticals, Inc., AMAG Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. are the leading companies in the market.

The high cost of treatment will hinder the market growth. Lack of awareness of the treatment will restrain the growth of market.

The loss of blood and decrease in red blood cell production can lead to anaemia due to an iron deficiency or an increase in red blood cell destruction by haemolysis. The main cause of anaemia is iron deficiency.

MegaPro Biomedical and Nemysis are the emerging drugs which would drive the market growth.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER